| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cuprina Holdings (Cayman) Limited
$2.72
-0.01 (-0.36%)
Market Cap
2.50 M
EPS
-0.17
P/E Ratio
-
Value Trade
66.32 K
-8.41 %
Week
-24.65 %
1 Month
38.67 %
3 Month
-15 %
6 Month
-93.87 %
5 Year
-93.87 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
11.69 K
52 Week Range
1.76 - 19.60
% held by Insiders
65.66 %
% held by Institutions
1.73 %
Enterprise Value
-61.15 K
Total Shares
920.63 K
Short %
1.89 %
Float Shares
7.37 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CUPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CUPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CUPR▲ +111.8%on this news
Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
Cuprina Holdings has received FDA 510(k) clearance for MEDIFLY Maggots™, marking it as the first U.S. product using Lucilia cuprina for maggot debridement therapy. This product is intended for treating non-healing necrotic wounds and is expected to be available to U.S. wound-care providers soon. The clearance positions Cuprina uniquely in the market, allowing for broader international regulatory pursuits.
Read more →CUPR▲ +64.7%on this news· ran to +249% by day 1shared move
Cuprina Holdings (Cayman) Limited Regains Compliance with Nasdaq Listing Requirements
Cuprina Holdings (Cayman) Limited has announced that it has regained compliance with Nasdaq Capital Markets Listing Requirements as of June 11, 2026. This follows a previous notification of non-compliance due to its stock price falling below $1.00 for 30 consecutive days. The company has successfully appealed the delisting determination, and its shares will continue to be traded on Nasdaq.
Read more →CUPR▼ -27.3%on this news
Cuprina Holdings Announces Completion of Reverse Stock Split and Requests a Hearing before the Nasdaq Hearings Panel to Maintain Listing
Cuprina Holdings has completed a reverse stock split and requested a hearing with the Nasdaq Hearings Panel to appeal a delisting determination due to non-compliance with the minimum bid price requirement. The company aims to regain compliance and maintain its Nasdaq listing. A hearing request will stay the suspension of its securities pending the Panel's decision.
Read more →CUPRCuprina Holdings announces 1-for-8 Share Consolidation
Cuprina Holdings announced a 1-for-8 share consolidation effective May 27, 2026, to comply with Nasdaq listing requirements. This move was approved by the board and shareholders, aiming to enhance the company's financial position. The consolidation will not change shareholders' percentage interests, although fractional shares will be rounded up.
Read more →CUPRCuprina Holdings (Cayman) Limited (Incorporated in the Cayman Islands with limited liability) Notice of Annual General Meeting of Shareholders To Be Held on
Cuprina Holdings (Cayman) Limited has announced its annual general meeting (AGM) scheduled for May 14, 2026, at 9:00 p.m. local time. Shareholders will vote on several key proposals, including the appointment of auditors and the re-election of current directors. Additional proposals include changes to share capital and voting rights, as well as an employee equity incentive plan. The meeting will be accessible to eligible attendees both in person and via live webcast.
Read more →CUPR▲ +8.1%on this news
Cuprina Holdings Announces Key Regulatory Milestone in Saudi Arabia and Strengthens Global Scientific Advisory Board
Cuprina Holdings has achieved a significant regulatory milestone with the Saudi Food and Drug Authority's classification of its MEDIFLY product as a Medical Device-Drug combination. This classification enables the company to proceed with commercial distribution across Saudi Arabia. Additionally, Cuprina has expanded its Medical and Scientific Advisory Board by appointing Dr. Enming Yong, enhancing its clinical governance and strategic direction.
Read more →CUPR▼ -6.6%on this news
CUPRINA HOLDINGS (CAYMAN) LIMITED INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Financial Statements: Unaudited Condensed Consolidated Balance Sheets as of
Cuprina Holdings (Cayman) Limited released its index to unaudited condensed consolidated financial statements. However, the document contains a significant amount of technical terminology without presenting specific financial metrics or insights. This lack of clarity could lead to uncertainties regarding the company's financial status. Stakeholders may find it challenging to assess the company’s performance based solely on the provided information.
Read more →CUPR▼ -6.6%on this news
Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth
Cuprina Holdings (Cayman) Limited reported its financial results for the six months ending June 30, 2025, showing a revenue decline and an increase in net loss compared to the previous year. Despite these setbacks, the company highlighted achievements in product diversification and geographical expansion, including the construction of an IVF media production facility and a partnership for medical waste recycling technology. For 2026, Cuprina anticipates multiple revenue streams and intends to strengthen its leadership to facilitate growth and long-term profitability.
Read more →CUPRCuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Cuprina Holdings (Cayman) Limited has received a notification from Nasdaq regarding noncompliance with minimum bid price requirements. The company has 180 days to regain compliance by maintaining a bid price of at least $1 per share. If compliance is not achieved, Cuprina may seek additional time or face delisting. The shares will continue to trade as usual during this period.
Read more →CUPRCuprina forms Joint Venture Company with Aiodine Laboratory to Develop and Market Novel Iodine-based Solution as New Wound Care Therapy
Cuprina Holdings has announced a joint venture with Aiodine Laboratory to develop a novel iodine-based disinfectant solution for wound care. The companies plan to initiate clinical studies in 2026, focusing on antiseptic applications and personal care. Early studies indicated promising results in wound healing without toxicity. With the growing global wound care market, this collaboration could enhance treatment options for chronic wounds.
Read more →CUPR▲ +19.1%on this news
Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies
Cuprina Holdings has signed a Memorandum of Understanding with Singapore Biowaste Solutions to integrate its medical waste recycling technology into SBS's facility. This collaboration aims to reduce reliance on incineration and enhance recycling efficiency while developing revenue-sharing models. The technology, developed over 20 years, is expected to comply with Singapore's environmental standards and commence operations by the end of 2026.
Read more →CUPRCuprina to Present Live, Answer Questions, at Skyline Signature Series™ on October 8th, 2025, at 11:00 AM ET
Cuprina Holdings will present at the Skyline Signature Series on October 8, 2025, at 11:00 AM ET. The event will be interactive, allowing investors to ask questions in real-time. This initiative aims to enhance communication between the company and financial professionals. Pre-registration is required for attendees.
Read more →CUPR▲ +12.2%on this news· ran to +159% by day 1
Cuprina Secures Exclusive Rights to Southeast Asia’s First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
Cuprina Holdings has acquired exclusive rights to a pioneering medical waste recycling technology in Southeast Asia, developed under UNIDO and GEF oversight. This technology offers a sustainable alternative to incineration, sterilizing and recycling medical waste into valuable materials. Cuprina plans to establish a facility in Singapore and expand operations across the region, addressing growing environmental concerns.
Read more →CUPR▲ +9.2%on this news· ran to -20% by day 1
Cuprina Reaffirms Commitment to Shareholders and Patients Following Recent Stock Market Activity
Cuprina Holdings has addressed recent stock market volatility, reassuring shareholders of its operational health and commitment to advancing its biotherapeutic pipeline. The company reported no known operational issues causing the volatility and highlighted ongoing regulatory milestones, including FDA submissions. Cuprina emphasizes transparency and integrity in its communications with stakeholders.
Read more →CUPR▲ +5%on this news
Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market
Cuprina Holdings has appointed Dr. Ronald Sherman as Medical and Scientific Director, effective September 2025. The company has also secured a license to market FDA-approved medical maggots for debridement therapy in the U.S. This strategic move aims to enhance clinical expertise and regulatory support for their innovative therapies, with a focus on expanding market presence.
Read more →CUPRCuprina Provides Update on Research Studies with Three Leading Education Institutes
Cuprina Holdings has announced progress in three research studies with top educational institutions in Singapore, focusing on the development of collagen peptides from bullfrog skin. These peptides are being explored for various applications, including cosmeceuticals and wound care. The studies aim to enhance product offerings and capitalize on the growing collagen market.
Read more →CUPRCuprina Completes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries
Cuprina Holdings has established a new laboratory in Saudi Arabia to manufacture its MEDIFLY maggot debridement therapy for chronic wounds, aiming to supply the MENA region. Additionally, the company has obtained exclusive rights to market medicinal leeches in GCC countries, which are used for various medical treatments. These developments are expected to enhance Cuprina's market presence and revenue.
Read more →CUPR▲ +5.8%on this news
Cuprina Holdings Announces Closing of Underwriter’s Over-Allotment Option in Connection with Initial Public Offering
Cuprina Holdings has successfully closed the sale of an additional 450,000 Class A ordinary shares through the full exercise of the underwriter's over-allotment option during its initial public offering. This has resulted in total gross proceeds of $13.8 million. The offering was conducted in compliance with SEC regulations, enhancing investor confidence.
Read more →CUPRCuprina Holdings Announces Completion, Receipt of Certification and License, for IVF Media Production Facility Built in Collaboration with Ferti-Craft Pte Ltd.
Cuprina Holdings has completed the construction of an IVF media production facility in Singapore and received ISO 13485 certification. This facility, built in collaboration with Ferti-Craft, aims to produce 14 SKUs of IVF media products. The companies plan to submit regulatory dossiers to the Singapore Health Sciences Authority for approval, with commercial production expected by late 2026.
Read more →CUPRCuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
Cuprina Holdings (Cayman) Limited has successfully closed its initial public offering, raising $12 million by selling 3 million Class A Ordinary Shares at $4.00 each. The funds will be used for market expansion, research and development, and general corporate purposes. The company aims to enhance its product portfolio in chronic wound care and cosmeceuticals.
Read more →CUPR▼ -9.9%on this newsshared move
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering
Cuprina Holdings (Cayman) Limited has announced the pricing of its initial public offering, aiming to raise $12 million by offering 3,000,000 Class A Ordinary Shares at a price of $4.00 each. The underwriter has a 45-day option to purchase an additional 450,000 shares. Trading is anticipated to commence on NASDAQ under the ticker symbol 'CUPR' on April 10, 2025, with closure of the offering expected the following day. Legal counsel has been engaged to facilitate the process, with necessary regulatory filings having been made to the U.S. SEC.
Read more →Competitive Position
How CUPR ranks across every disease it competes inCompetitive Position is a premium feature
See how CUPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial